Enliven Therapeutics, Inc. ELVN 深 滬
已收盤 11-06 16:00:00 美东时间
49.43
+4.640
+10.36%
華盛通- 最 高49.6585
- 今 開46.19
- 成交量 96.96万股
- 最 低 44.55
- 昨 收 44.79
- 總市值 36.22亿
- 52周最高 62.32
- 市盈率 靜 --
- 換手率 1.32%
- 52周最低 14.785
- 委 比 -87.11%
- 總股本 7327.08万
- 歷史最高 250.84
- 量 比 0.55
- 振 幅 11.41%
- 歷史最低 3.896
- 每 手 1
- 風險率 13.12%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Guggenheim Reiterates Buy on Enliven Therapeutics, Maintains $78 Price Target
Guggenheim analyst Michael Schmidt reiterates Enliven Therapeutics (NASDAQ:ELVN) with a Buy and maintains $78 price target.
今天 00:26
美股大行评级 | 潜在涨幅523.44%！HC Wainwright & Co.上调Annexon目标价至25美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Annexon"买入"评级，目标价从14美元升至25美元；HC Wainwright & Co.：维持Alto Neuroscience"买入"评级，目标价从55美元升至60美元
10-20 12:36
HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $73
HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $65 to $73.
10-19 18:28
美股大行评级 | 潜在涨幅1654.39%！Ascendiant Capital上调NRX Pharmaceuticals(NRXP)目标价至50美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从49美元升至50美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从24美元升至25美元
10-02 08:33
JP Morgan Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $75
JP Morgan analyst Priyanka Grover initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $75.
10-01 22:46
Enliven Therapeutics to Present at Upcoming Investor Conferences
BURLINGAME, Calif., Sept. 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and ...
09-04 04:05
Reported Earlier, Enliven To Present New ELVN-001 Blood Cancer Trial Data At September Medical Meeting
Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that the Company will present data from the ENABLE Phase 1 clinical trial of ELVN-001 in an oral and ...
09-01 15:57
美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
Enliven Therapeutics Inc. (NASDAQ:ELVN) drew an Outperform rating from William Blair on Tuesday as the firm initiated coverage, citing the potential for lead drug candidate ELVN-001 to reshape treatment of chronic myeloid leukemia (CML). ELVN-001 Shows Positive Phase 1 Data Enliven Therapeutics’ lea...
08-19 01:58
Mizuho Maintains Outperform on Enliven Therapeutics, Raises Price Target to $73
Mizuho analyst Salim Syed maintains Enliven Therapeutics (NASDAQ:ELVN) with a Outperform and raises the price target from $62 to $73.
08-18 19:48
